Nuevolution and bromodomain selective BET inhibitors

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Nuevolution and bromodomain selective BET inhibitors

posted on Nov 27, 2017 12:54PM

Looks like they've only disclosed a pre-clinical program related to bromodomain-1 (BD1) selective BET inhibitors, but I wouldn't be surprised if they have other compounds in their library that are BD2-selective. It's all pre-clinical right now.

Nuevolution to Present New Data on its BET BD1 Program Supporting Effect in Psoriasis/Atopic Dermatitis

https://nuevolution.com/pipeline/brd-bd1/

"Nuevolution is developing compound classes exhibiting BET subdomain selectivity, and we are currently exploring the use of such compounds in various disease settings, including inflammation."

3 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply